The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Core Insights - Pharmaceutical stocks have shown significant growth this year, with the iShares U.S. Pharmaceuticals ETF up nearly 29% year to date and 11% over the past month [1] - AbbVie is highlighted as a key stock to watch, focusing on treatments across various disease areas including immunology and oncology [1] Financial Performance - AbbVie reported quarterly results on October 31, exceeding Wall Street forecasts with sales of $15.78 billion, a 9.1% increase compared to expectations of $15.59 billion [2] - Earnings per share were $1.86, surpassing the expected $1.77 by 11 cents [2] Drug Sales Performance - AbbVie's top-performing drugs showed remarkable sales growth: - Skyrizi sales increased by 46.8% to $4.7 billion [3] - Rinvoq sales rose by 35.3% to $2.18 billion [3] - Humira generated $993 million, up 55.4% year-over-year [3] Future Projections - Management projects that Rinvoq could reach $11 billion in annual revenue by 2027, while Skyrizi may hit $20 billion [4] - AbbVie continues to expand its drug pipeline through acquisitions, indicating strong future growth potential [4]